Pfizer Aktie News

A tobacco giant shifting to smoke-free products just raised its dividend by 8.9% as next-generation nicotine wins an ever-increasing slice of revenue. A pharmaceutical company trades at 8 times forward earnings with a 7% yield as it raises revenue guidance and reenters the obesity drug market.

There's no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment.

Pfizer currently has a 7% yield, and the company is making important business moves. Bristol Myers Squibb has a 5.6% yield and has been building its drug pipeline with acquisitions.

Anti-obesity drugs are being considered for a range of addictive behaviors. Pfizer just acquired a next-generation, clinical-stage maker of obesity treatments.

Pfizer's stock has been trading at low levels for a while. Diminished growth and concerns about the future have investors thinking twice about the stock.

Every large company has to deal with both industry conditions and the efficiency of their own business. Pfizer is making the changes needed to deal with the world around it and handle normal issues in the drug sector.

Kenvue was spun off from Johnson & Johnson in mid-2023, and its life is starting out a little rough. Pfizer is working through typical drug industry issues, but there's a notable dividend risk to consider.